Scobell Rebecca, Pradhan Madhura
Pediatric Nephrology, Perelman School of Medicine University of Pennsylvania, Children's Hospital of Philadelphia, PA, United States of America.
Clinical Pediatrics, Perelman School of Medicine University of Pennsylvania, Children's Hospital of Philadelphia, PA, United States of America. Correspondence to: Dr Madhura Pradhan, Children's Hospital of Philadelphia, PA 19104, USA.
Indian Pediatr. 2020 May 15;57(5):401-406.
Lupus nephritis affects 50-75% of all children with systemic lupus erythematosus with a higher prevalence in Asians. It remains a major contributor to morbidity and mortality in childhood onset lupus. Proliferative lupus nephritis (class III and class IV) warrants aggressive treatment to prevent progression to end stage renal disease. Newer immunosuppressive agents available in the last decade offer more options to treat lupus nephritis. Despite guidelines from professional bodies, there remains a lack of consensus on the treatment of refractory disease and duration of maintenance therapy. We review the treatment options for pediatric patients with lupus nephritis based on studies and published guidelines in the last decade, and highlight opportunities for continued improvement in care.
狼疮性肾炎影响50%至75%的系统性红斑狼疮患儿,在亚洲人中的患病率更高。它仍然是儿童期发病狼疮患者发病和死亡的主要原因。增殖性狼疮性肾炎(III级和IV级)需要积极治疗以防止进展为终末期肾病。过去十年中可用的新型免疫抑制剂为治疗狼疮性肾炎提供了更多选择。尽管有专业机构的指南,但对于难治性疾病的治疗和维持治疗的持续时间仍缺乏共识。我们根据过去十年的研究和已发表的指南回顾了小儿狼疮性肾炎患者的治疗选择,并强调了持续改善护理的机会。